Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

E. Goekkurt · SciRah

Researcher profile · Semantic Scholar

E. Goekkurt

Share profile

E. Goekkurt — researcher profile on SciRah

h-index: 25
Works: 114
Citations: 5,649

Most-cited papers

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Jong-Mu Sun, Lin Shen, M. Shah, P. Enzinger +21 more
2021The Lancet1,284 citations Open access
Semantic Scholar
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.
K. Shitara, E. Van Cutsem, Y. Bang, C. Fuchs +24 more
2020JAMA Oncology1,034 citations Open access
Semantic Scholar
Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer.
Thierry Andre, E. Élez, E. Van Cutsem, Lars Henrik Jensen +23 more
2024New England Journal of Medicine216 citations
Semantic Scholar
Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial
Sylvie Lorenzen, T. Götze, P. Thuss-Patience, Matthias Biebl +22 more
2023Journal of Clinical Oncology180 citations
Semantic Scholar
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
V. Kunzmann, J. Siveke, H. Algül, E. Goekkurt +33 more
2020The Lancet Gastroenterology and Hepatology156 citations
Semantic Scholar
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial.
Thierry Andre, E. Élez, H. Lenz, Lars Henrik Jensen +25 more
2025The Lancet154 citations
Semantic Scholar
LBA8_PR Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study
Kiyoko Kato, J.-M. Sun, M. Shah, P. Enzinger +16 more
2020Annals of Oncology136 citations Open access
Semantic Scholar
FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2–Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group
R. Hofheinz, K. Merx, G. Haag, C. Springfeld +21 more
2022Journal of Clinical Oncology83 citations
Semantic Scholar
Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: Final results of the PETRARCA multicenter randomized phase II trial of the AIO.
R. Hofheinz, G. Haag, T. Ettrich, K. Borchert +16 more
202077 citations
Semantic Scholar
Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)
D. Modest, M. Karthaus, S. Fruehauf, U. Graeven +17 more
2021Journal of Clinical Oncology74 citations Open access
Semantic Scholar
Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial.
A. Stein, L. Paschold, J. Tintelnot, E. Goekkurt +22 more
2022JAMA Oncology60 citations Open access
Semantic Scholar
Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)
I. Hartlapp, D. Valta-Seufzer, J. Siveke, H. Algül +17 more
2022ESMO Open42 citations Open access
Semantic Scholar
53MO Nal-IRI and 5-FU/LV compared to 5-FU/LV in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies (NALIRICC – AIO-HEP-0116)
A. Vogel, P. Wenzel, G. Folprecht, P. Schütt +15 more
2022Annals of Oncology42 citations Open access
Semantic Scholar
Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Final results of the phase II AVETUX trial (AIO-KRK-0216).
A. Stein, M. Binder, E. Goekkurt, S. Lorenzen +12 more
202039 citations
Semantic Scholar
1421MO Final results and subgroup analysis of the PETRARCA randomized phase II AIO trial: Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma
S. Al-Batran, G. Haag, T. Ettrich, K. Borchert +16 more
202030 citations Open access
Semantic Scholar
1429P Pathological regression in patients with microsatellite instability (MSI) receiving perioperative atezolizumab in combination with FLOT vs. FLOT alone for resectable esophagogastric adenocarcinoma: Results from the DANTE trial of the German Gastric Group at the AIO and SAKK
S. Al-Batran, S. Lorenzen, N. Homann, P. Thuss-Patience +16 more
2021Annals of Oncology29 citations Open access
Semantic Scholar
Pembrolizumab with or without chemotherapy vs chemotherapy in patients with advanced G/GEJ cancer (GC) including outcomes according to Microsatellite Instability-High (MSI-H) status in KEYNOTE-062
K. Shitara, E. Van Cutsem, Y. Bang, C. Fuchs +15 more
2019Annals of Oncology29 citations Open access
Semantic Scholar
Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7): Results of the phase II-portion—A multicenter, randomized phase II/III trial of the German AIO and Italian GOIM.
S. Al-Batran, R. Hofheinz, H. Schmalenberg, D. Strumberg +16 more
202027 citations
Semantic Scholar
Conversion rate in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- or FOLFIRINOX-based induction chemotherapy (NEOLAP): Final results of a multicenter randomised phase II AIO trial
V. Kunzmann, H. Algül, E. Goekkurt, G. Siegler +16 more
2019Annals of Oncology27 citations Open access
Semantic Scholar
Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)
J. Tintelnot, E. Goekkurt, M. Binder, P. Thuss-Patience +13 more
2020BMC Cancer26 citations Open access
Semantic Scholar
Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial
Alexander Stein, E. Goekkurt, S. Al-Batran, N. Moosmann +15 more
2025Nature Medicine25 citations Open access
Semantic Scholar
Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM
T. Goetze, R. Hofheinz, T. Gaiser, H. Schmalenberg +19 more
2023International Journal of Cancer25 citations
Semantic Scholar
Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial
K. Shitara, M. Di Bartolomeo, M. Mandalà, M. Ryu +15 more
2023Journal for ImmunoTherapy of Cancer24 citations Open access
Semantic Scholar
Translational analysis and final efficacy of the AVETUX trial – Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer
J. Tintelnot, I. Ristow, M. Sauer, D. Simnica +23 more
2022Frontiers in Oncology22 citations Open access
Semantic Scholar
Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1–positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial.
Z. Wainberg, K. Shitara, E. Van Cutsem, L. Wyrwicz +16 more
2022Journal of Clinical Oncology20 citations Open access
Semantic Scholar
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel: Results from the phase II RAMIRIS Study of the AIO.
S. Lorenzen, P. Thuss-Patience, C. Pauligk, E. Goekkurt +10 more
202018 citations
Semantic Scholar
Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061
E. Van Cutsem, M. Amonkar, C. Fuchs, M. Alsina +12 more
2021Gastric Cancer16 citations Open access
Semantic Scholar
Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer
W. Mansoor, Seongjung Joo, J. M. Norquist, K. Kato +16 more
2024The Oncologist14 citations Open access
Semantic Scholar
Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212)
A. Stahler, B. Hoppe, Il-Kang Na, Luisa Keilholz +18 more
2023Journal of Clinical Oncology14 citations
Semantic Scholar
Ramucirumab, Avelumab, and Paclitaxel as Second-Line Treatment in Esophagogastric Adenocarcinoma
P. Thuss-Patience, A. Högner, E. Goekkurt, M. Stahl +13 more
2024JAMA Network Open13 citations Open access
Semantic Scholar
Pembrolizumab plus FLOT vs FLOT as neoadjuvant and adjuvant therapy in locally advanced gastric and gastroesophageal junction cancer: Interim analysis of the phase 3 KEYNOTE-585 study.
S. Al-Batran, K. Shitara, G. Folprecht, M. Moehler +13 more
2024Journal of Clinical Oncology13 citations Open access
Semantic Scholar
Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212)
K. Heinrich, M. Karthaus, S. Fruehauf, U. Graeven +16 more
2023ESMO Open11 citations Open access
Semantic Scholar
Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorectal cancer—final results of the AIO CHARTA trial
H. Schmoll, Julia Mann, F. Meinert, B. Garlipp +19 more
2023British Journal of Cancer11 citations Open access
Semantic Scholar
LBA54 Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): Results of the randomized phase II INTEGA trial (AIO STO 0217)
A. Stein, L. Paschold, J. Tintelnot, E. Goekkurt +15 more
2021Annals of Oncology11 citations Open access
Semantic Scholar
Efficacy of ramucirumab combination chemotherapy as second‐line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first‐line therapy
M. Masetti, S. Al-Batran, T. Goetze, P. Thuss-Patience +13 more
2024International Journal of Cancer10 citations Open access
Semantic Scholar
LBA59 Modified FOLFOX plus/minus nivolumab and ipilimumab vs FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Final results of the IKF-AIO-Moonlight trial
S. Lorenzen, T. Goetze, P. Thuss-Patience, J. Riera Knorrenschild +16 more
2024Annals of Oncology8 citations Open access
Semantic Scholar
Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic colorectal cancer: Subgroup analysis of patients treated within the PanaMa trial (AIO KRK 0212)
G. Sommerhäuser, M. Karthaus, A. Kurreck, A. Ballhausen +16 more
2023International Journal of Cancer8 citations Open access
Semantic Scholar
Ramucirumab beyond progression plus TAS‐102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab‐based therapy
T. Goetze, A. Stein, S. Lorenzen, Timorshah Habibzada +8 more
2023International Journal of Cancer8 citations Open access
Semantic Scholar
Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415)
S. Lorenzen, Alix Schwarz, C. Pauligk, E. Goekkurt +11 more
2023BMC Cancer8 citations Open access
Semantic Scholar
Lorlatinib Induces Durable Disease Stabilization in a Pancreatic Cancer Patient with a ROS1 p.L1950F Mutation: Case Report
J. Velthaus, Peter Iglauer, R. Simon, C. Bokemeyer +5 more
2021Oncology Research and Treatment8 citations
Semantic Scholar
Chemotherapy for patients with circulating tumour DNA-positive, stage II colon cancer (CIRCULATE)-an AIO/ABCSG trial.
G. Folprecht, S. Stasik, A. Reinacher-Schick, L. Weiss +20 more
2026Annals of Oncology7 citations Open access
Semantic Scholar
Health-related quality of life (HRQoL) of pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase III KEYNOTE-590 study.
W. Mansoor, A. Kulkarni, Ken Kato, Jong-Mu Sun +16 more
20217 citations
Semantic Scholar
1623P Pelareorep (pela) + atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients: Results from the GOBLET study
D. Arnold, E. Goekkurt, A. Stein, U. Martens +6 more
2023Annals of Oncology6 citations Open access
Semantic Scholar
1203O FOLFOX plus nivolumab and ipilimumab versus FOLFOX induction followed by nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Results from the randomized phase II Moonlight trial of the AIO
S. Lorenzen, P. Thuss-Patience, G. Folprecht, J. R. Knorrenschild +16 more
2022Annals of Oncology6 citations Open access
Semantic Scholar
1424MO Perioperative FLOT plus ramucirumab versus FLOT alone for resectable esophagogastric adenocarcinoma– Updated results and subgroup analyses of the randomized phase II/III trial RAMSES/FLOT7 of the German AIO and Italian GOIM
S. Al-Batran, R. Hofheinz, H. Schmalenberg, D. Strumberg +16 more
20206 citations Open access
Semantic Scholar
1494P Updated safety data of the DANTE trial: Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma - A randomized, open-label phase II trial of the German Gastric Group at the AIO and SAKK
S. Al-Batran, S. Lorenzen, P. Thuss-Patience, M. Schenk +16 more
20206 citations Open access
Semantic Scholar
LBA80 Regorafenib plus nivolumab vs investigator’s choice of chemotherapy in previously treated gastric or gastroesophageal cancer: INTEGRATE IIb, a randomized phase 3 AGITG Intergroup [NHMRC-CTC/IKF/AIO, ACCRU, TCOG/NHRI] study
D. Goldstein, K. Sjoquist, D. Espinosa, S. Rha +16 more
2025Annals of Oncology5 citations
Semantic Scholar
Panitumumab plus 5-fluorouracil and folinic acid or 5-fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer (PanaMa, AIO KRK 0212): final efficacy analysis of a randomised, open-label, phase 2 trial
A. Stahler, Meinolf Karthaus, S. Fruehauf, U. Graeven +16 more
2024EClinicalMedicine5 citations Open access
Semantic Scholar
650 Pelareorep combined with atezolizumab and chemotherapy demonstrates encouraging results as first-line treatment in advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients – interim results from the GOBLET study
D. Arnold, M. Collienne, A. Stein, G. Ungerechts +7 more
2022Regular and Young Investigator Award Abstracts5 citations Open access
Semantic Scholar
Interim safety analysis of the DANTE trial: Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma—A randomized, open-label phase II trial of the German Gastric Group at the AIO and SAKK.
N. Homann, S. Lorenzen, M. Schenk, P. Thuss-Patience +16 more
20205 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

C. Pauligk×17
Invite
C. Pauligk — researcher profile on SciRah
S. Al-Batran×14
Invite
S. Al-Batran — researcher profile on SciRah
D. Pink×13
Invite
D. Pink — researcher profile on SciRah
T. Goetze×12
Invite
T. Goetze — researcher profile on SciRah

×12

Invite

S. Lorenzen — researcher profile on SciRah

A. Kretzschmar×11

Invite

A. Kretzschmar — researcher profile on SciRah

Invite

T. Ettrich — researcher profile on SciRah

Invite

U. Lindig — researcher profile on SciRah

Invite

R. Hofheinz — researcher profile on SciRah

Invite

N. Homann — researcher profile on SciRah

S. Angermeier×8

Invite

S. Angermeier — researcher profile on SciRah

Invite

G. Siegler — researcher profile on SciRah